Publications
106
Citations
752
Est. group size
~12
Recurring co-author estimate
Active years
17
Publishing since 2010
Mahesh R. Nepal's research focuses on how drugs move into and out of liver cells, particularly through transporter proteins called OATPs (organic anion transporting polypeptides), and how this affects drug safety and interactions. Much of the recent work examines whether cancer drugs like tyrosine kinase inhibitors and BTK inhibitors interact with these transporters or cause side effects such as nerve damage, which is relevant to designing safer cancer treatments. This research sits at the intersection of pharmacology and cancer therapeutics, using laboratory assays to predict how drugs behave in patients.
Publication output was relatively steady at a modest pace through the mid-2010s to early 2020s, then increased sharply in 2024 and 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Pacific Blue Derivatives of Paclitaxel as Fluorescent Probes of OATP1B‐Type Transporters
Clinical and Translational Science · 2026
- Regulation of hepatic organic anion transporting polypeptide 1B-type transport function by the protein kinase LYN
Drug Metabolism and Disposition · 2025
- Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
Cancer Research Communications · 2025
- Preventing Vincristine-Induced Neurotoxicity by Nilotinib: Effects on Neuronal Transport and Anti-Leukemic Efficacy (Abstract ID: 168706)
Journal of Pharmacology and Experimental Therapeutics · 2025
- Supplementary Table 3 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
2025
- Supplementary Table 2 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
2025
- Supplementary Figure 1 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
2025
- Supplementary Table 1 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
2025
- Supplementary Table 4 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
2025
- Supplementary Table 5 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
2025
- Supplementary Data from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
2025
- Supplementary Figure 2 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen
2025
- Supplementary Figure S5 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
2025
- Supplementary Figure S3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
2025
- Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895
2025
- The American Journal of Gastroenterology×8
- Journal of Toxicology and Environmental Health×4
- Archives of Pharmacal Research×3
- Cancer Research Communications×3
- Journal of Clinical Oncology×3
- Anika T. Chowdhury
Medicine · The Ohio State University
- Zahra Talebi
Medicine · The Ohio State University
- Josie A. Silvaroli
Medicine · The Ohio State University
- Navjotsingh Pabla
Medicine · The Ohio State University
- Kevin M. Huang
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile